🔍 Vaxart Seeks Clarity as BARDA Funding Halts Again Vaxart reports a new stop-work order on a BARDA-funded, 10,000-participant Phase 2b trial of its oral COVID-19 vaccine candidate—despite having enrolled ~5,000 participants so far. The biotech says it has received no explanation for the termination and is actively seeking answers. Vaxart can continue follow-up for those already dosed, though new screening must stop. This development comes after a wild federal tug-of-war: Vaxart previously paused and then resumed the trial, only to have HHS halt most mRNA vaccine development under BARDA—yet Vaxart’s candidate is not an mRNA vaccine. The pause adds uncertainty to Vaxart’s oral vaccine ambitions—and underscores the ripple effects of shifting federal policies on biotech R&D. #Vaxart #BARDA #Biotech #COVID19Vaccine #ClinicalTrials #VaccinePolicy #FundingFreeze

🥇 Novartis Scores Third Phase 3 Win This Week with Ianalumab In a remarkable clinical milestone, Novartis has announced its third Phase 3 win this week for ianalumab—this time in primary immune thrombocytopenia (ITP). The B-cell–depleting antibody significantly extended time to treatment failure and boosted sustained platelet responses when paired with eltrombopag, compared to eltrombopag alone. This success follows two recent wins in Sjögren’s syndrome, where ianalumab achieved statistically significant improvements in disease activity. Together, these results position ianalumab as a breakthrough B-cell therapy in autoimmune medicine. #Novartis #Ianalumab #AutoimmuneDisease #ClinicalTrials #Phase3 #BiotechBreakthrough #Sjögrens #ITP #DrugDevelopment #Innovation

🚀 Bayer Bets Big on Undruggable KRAS — Up to $1.3B pact with Kumquat Biosciences to license a KRAS G12D inhibitor, a once-invincible oncogene mutation now entering clinical testing. Why this matters: The drug targets KRAS G12D, common in 38% of pancreatic cancer cases, 13% of colorectal, and 4% of NSCLC patients. Fierce BiotechReuters Kumquat handles Phase Ia trials; Bayer will lead global development and commercialization. PR NewswireReuters Deal includes tiered royalties, with Kumquat retaining the option for U.S. profit-loss sharing. ReutersPR Newswire Adds depth to Bayer’s precision oncology portfolio alongside darolutamide and sevabertinib. Fierce BiotechBioSpace This signals a bold move to tackle a high-unmet-need cancer target long deemed “undruggable.” #CancerResearch #Oncology #KRAS #PrecisionMedicine #PharmaDeals #DrugDevelopment #Biotech

🚀 PureTech Launches Celea Therapeutics to Transform Lung Disease Care 🌬️🔬 PureTech has unveiled Celea Therapeutics, a new venture focused on respiratory diseases. Led by former Teva North America CEO Sven Dethlefs, the spinout will advance its promising Phase 3–ready candidate, deupirfenidone (LYT-100), for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung conditions. Deupirfenidone—a deuterated version of pirfenidone—showed unprecedented stabilization of lung function in Phase 2b trials, with a lasting effect through 52 weeks and a better safety profile than current therapies. PureTech plans to bring this soap-mounted asset into Phase 3 after discussions with the FDA later this year. 👏 #Biotech #RespiratoryMedicine #IPF #DrugDevelopment #PureTech #CeleaTherapeutics #ClinicalTrials #Innovation #RareDisease

🚨 Pipeline Shake-Up at Gilead 🚨 Gilead Sciences has axed three R&D programs — including a Novo Nordisk-partnered MASH combo and two early-stage cancer drugs (DGKα inhibitor GS-9911 and MCL1 inhibitor zamzetoclax). The MASH candidate, combining cilofexor, firsocostat, and Novo’s semaglutide, completed Phase 2 last year but results remain undisclosed. Novo says it won’t pursue the combo solo. This move leaves Gilead’s fibrotic disease pipeline empty, signaling a sharpened focus on higher-priority programs after its HIV prophylactic launch. #Gilead #BiotechNews #ClinicalTrials #MASH #Oncology #DrugDevelopment #RDPipeline #PharmaUpdates

🚨 Major Breakthrough in Sjögren’s Syndrome! 🚨 Novartis has announced double Phase 3 wins for its dual-mechanism antibody ianalumab in the Neptunus 1 & 2 trials — marking the first-ever global Phase 3 studies to show a statistically significant reduction in disease activity for Sjögren’s disease. 🧪💉 This autoimmune condition, often misdiagnosed and with few treatment options, affects patients’ quality of life worldwide. Now, Novartis is preparing to take these results to regulators with the goal of launching the first targeted treatment for the disease. 🌍✨ After other Big Pharma players dropped their Sjögren’s programs, Novartis’ success could change the treatment landscape. #Novartis #ClinicalTrials #SjögrensSyndrome #AutoimmuneDisease #BiotechNews #DrugDevelopment #Phase3Win #MedicalBreakthrough

⚡ Cancer Vaccine Misses Mark — But FDA Still in Sight 🧬🎯 IO Biotech’s melanoma vaccine Cylembio, combined with Keytruda, narrowly missed statistical significance in a phase 3 trial (PFS HR: 0.77; p=0.056). Despite the setback, results showed median PFS of 19.4 months vs. 11 months with Keytruda alone, plus an encouraging OS trend. 📅 The company plans to meet with the FDA this fall to discuss a potential approval path. Unlike mRNA cancer vaccines, Cylembio is an off-the-shelf T-win platform product designed to stimulate T cells without added systemic toxicity. #CancerResearch #BiotechNews #Melanoma #ImmunoOncology #CancerVaccine #ClinicalTrials #FDA

🚀 $645M Lung Disease Deal Alert 🌬️💊 Expedition Therapeutics is licensing XH-S004 from Fosun Pharma for $17M upfront, with potential milestones up to $645M. The oral DPP-1 inhibitor—currently in Phase 2 for non-CF bronchiectasis and Phase 1b for COPD—aims to reduce inflammation in chronic lung diseases. 🌏 Fosun retains rights in mainland China, Hong Kong & Macau; Expedition takes the rest of the globe. 💡 No drug with this molecular mechanism has been globally approved—this could be a first. #Biotech #Pharma #LungDisease #DrugDevelopment #COPD #Bronchiectasis #HealthcareInnovation #ClinicalTrials #MergersAndAcquisitions

📉 Gilead returns rights to Arcus’ etrumadenant, stepping back from a key asset in their $725M cancer immunotherapy deal. 🔙 The move follows Arcus' decision not to pursue phase 3 for etrumadenant in metastatic colorectal cancer, despite an FDA-confirmed path to market. 💸 Arcus reported a $143M revenue catch-up tied to the returned license and paused development. Gilead still holds licenses to TIGIT antibodies like domvanalimab, CD73 inhibitor quemliclustat, and PD-1 drug zimberelimab—but this return marks another setback in their Arcus alliance. #Biotech #Oncology #Immunotherapy #Gilead #ArcusBiosciences #DrugDevelopment #FierceBiotech #PharmaNews #CancerResearch #LicensingDeals #TIGIT #ColorectalCancer

🚀 Minghui Pharmaceutical lands $131M in a “pre-IPO” round to accelerate its launch and pipeline! 💸 Led by OrbiMed and Qiming Venture Partners, the Shanghai biotech will: ✅ Support the potential launch of MH004, a topical pan-JAK inhibitor for dermatitis (Ph3, under review in China) 🧬 Advance oncology & immunology programs, including: MHB039A (PD-1/VEGF bispecific) MHB036C (TROP-2 ADC) MHB088C (B7-H3 ADC, licensed in China to Qilu for $38M upfront) 📈 CEO Guoqing Cao calls it a key milestone in building a “globally competitive pipeline.” #Biotech #FundingNews #PharmaInnovation #JAKinhibitors #AntibodyDrugConjugates #MinghuiPharma #VentureCapital #OrbiMed #Qiming #ChinaBiotech #Dermatitis #LungCancer #ADC #FierceBiotech

🔁 Eli Lilly hits reset on its pain & inflammation pipeline in a major Q2 R&D clearout. ❌ Mazisotine (licensed from Centrexion) is out after underwhelming Ph2 results for diabetic neuropathic pain. ✅ In comes STC-004, a NaV1.8 inhibitor from its SiteOne acquisition, targeting the same pain pathway as Vertex's Journavx. Also scrapped: A Kv1.3 antagonist for psoriasis (originally from D.E. Shaw Research) An itaconate mimetic from Sitryx An siRNA SCAP inhibitor for liver disease 💰 Strategic pruning post-acquisition spree. 🎯 Focus sharpening across pain, autoimmune, and metabolic indications. #EliLilly #Biotech #PharmaPipeline #ClinicalTrials #DrugDevelopment #PainManagement #R&D #FierceBiotech #PharmaNews #HealthcareInnovation #SiteOne #Vertex #molecularmedicine

🚀 Strand Therapeutics lands $153M Series B to push its self-replicating mRNA cancer therapies deeper into the clinic! Backed by industry giants like Regeneron, Amgen, and Eli Lilly, Strand is reshaping the future of oncology. Their lead candidate STX-001 shows early complete & partial responses in tough-to-treat tumors, with systemic immune activation. Up next: STX-003, a liver-sparing, tumor-targeted breakthrough. 🧬 Programmable mRNA = the next frontier. 📍 Precision. Power. Possibility. #Biotech #mRNA #CancerResearch #VC #PrecisionMedicine #Oncology #StrandTherapeutics #Immunotherapy #ClinicalTrials #StartupFunding #FierceBiotech #SeriesB #HealthcareInnovation

🔄 Terns to Halt Metabolic Trials After 2025, Shifts to Partnering Mode 💡 In a pivotal pivot, Terns Pharmaceuticals has announced it will halt funding for metabolic disease trials after 2025, including its lead GLP‑1 candidate TERN‑601 in obesity. Instead, it plans to seek partners or divest its obesity/metabolic assets, setting a new strategic direction. ⚙️ Why this matters: The FALCON Phase 2 obesity trial is enrolling well, with weight-loss results anticipated in Q4 2025. TERN‑701, targeting CML, is progressing quickly toward data readouts in Q4 2025, with a reported cash runway into 2028. The shift signals a move away from a crowded metabolic space and toward collaboration—freeing resources for assets with higher differentiation or near-term value. As obesity markets become increasingly competitive, Terns is betting that partnering its metabolic pipeline now could maximize return—and reduce R&D burn. #TernsPharma #ObesityDrug #GLP1 #BiotechStrategy #Partnering #MetabolicDisease #OncologyShift

🇯🇵 Astria Licenses Navenibart to Kaken for Japan in $32M Deal 🧬 Strategic global move by Astria: the company has inked a Japan-exclusive licensing deal with Kaken Pharmaceutical for its lead HAE antibody navenibart, capturing $16M upfront plus up to $16M in milestones, and royalties up to 30% of net sales. 🎯 👉 Kaken will actively support Phase 3 ALPHA‑ORBIT development in Japan, handle local regulatory approvals, and cover a portion of trial costs. Navenibart’s story: In the Phase 1b/2 ALPHA‑STAR trial, 1–2 doses over six months cut HAE attack rates by 90–95%, and 67% of patients remained attack-free The Phase 3 program, initiating in Q1 2025, features both every-3-month and every-6-month dosing schemes, with global registration targeted by early 2027  This partnership deepens Astria’s Japan strategy, accelerates clinical execution, and expands its financial runway through 2028—all while positioning navenibart to be a market-leading, low-burden preventative therapy for HAE. #AstriaTherapeutics #Kaken #Navenibart #HAE #RareDisease #BiotechDeals #JapanPharma

🔬 Alltrna Slims Down Ahead of Its tRNA Medicines’ First Human Trial Flagship Pioneering-backed Alltrna is repositioning as it nears its first clinical milestone—cutting 8 jobs (12%) to refine operations around its upcoming tRNA-based therapy, engineered to tackle Stop Codon Diseases like PKU and organic acidemias. Why this matters: Alltrna's cutting-edge platform uses AI/ML to design tRNAs that ‘read through’ premature stop codons, enabling protein restoration in a broad class of genetic diseases (~10% of rare disorders) Despite the recent layoff, leadership says the clinical strategy is intact, with full focus on transitioning from preclinical to first-in-human studies The move echoes broader biotech realities: carefully calibrating scale and runway before clinic—with >$109M raised to date, including Flagship’s initial $50M commitment Alltrna represents a pioneering approach—tRNA medicines could eventually treat thousands of diseases caused by the same genetic logic. As the platform enters the clinic, this workforce adjustment signals readiness and precision. 🧬 #Alltrna #FlagshipPioneering #tRNAMedicine #RareDisease #Preclinical #BiotechRestructuring #StopCodonDisease

🚨 GAO Says NIH Broke the Law by Withholding $8B in Research Grants 💸 A major blow to actions aimed at cutting research funding: the Government Accountability Office (GAO) has ruled that the NIH illegally withheld and canceled over $8 billion in grants—terminating 1,800 awards and freezing new funding processes, violating the Impoundment Control Act of 1974. Here’s what happened: NIH canceled existing and paused new grants in early 2025 under executive orders, blocking critical peer-review steps and delaying funding to thousands of researchers. Between February and June, NIH disbursed billions less than the prior year—constituting improper “impoundment” under federal appropriations law. GAO found no legal pretext to justify these actions and warned they undermine Congress’s constitutional funding authority. Earlier court rulings also deemed cuts targeting DEI-linked and public health research void and illegal. While GAO can’t force reinstatement, its conclusion gives legal cover to Congress and courts to push back—and spotlights widespread disruption across scientific, medical, and public health research networks. #NIH #GAO #ScienceFunding #ImpoundmentControlAct #MedicalResearch #PublicHealth #CongressOversight

🚫 Vertex Scraps VX‑993 Next‑Gen Pain Pill After Phase 2 Miss – Journavx Expansion Scaled Back Tough week for Vertex’s pain strategy: VX‑993, the new NaV1.8 inhibitor designed to outperform Journavx, failed all three dose arms in a Phase 2 bunionectomy trial. Pain relief did not reach statistical significance vs placebo or hydrocodone/acetaminophen. As a result, Vertex is halting development of VX‑993 as monotherapy for acute pain. Regulatory feedback also shut down broader label plans: Vertex will no longer pursue Journavx approval in lumbosacral radiculopathy, and is now refocusing on the smaller diabetic neuropathy market (~20%). Even with strong Q2 performance (12% sales growth, $2.96B revenue, EPS $4.52), shares plunged 14–17% post-announcement. LinkedIn 15Barron's 15Reuters 15LinkedIn 1Reuters 1Reuters 10Reuters 10Applied Clinical Trials 10 The failure underscores broader challenges in advancing NaV1.8 inhibitors beyond Journavx’s platform. Vertex now must rebuild the growth outlook for its pain portfolio amid dampened investor optimism—while counting on cystic fibrosis drugs and gene therapies to carry the pipeline forward. #Vertex #PainTherapeutics #NonOpioidPain #Journavx #NaV1_8 #VX993 #ClinicalTrials #DrugFailure #BiotechFinance

🛑 BioMarin Ends PKU Program BMN 390 After Immunogenicity Shortfall — Eyes Next Moves BioMarin has quietly pulled the plug on BMN 390, a preclinical PKU (phenylketonuria) therapy once positioned to improve on its existing Palynziq® treatment. Despite its promise—including the use of the novel POEGMA polymer to reduce immune reactions and improve injection tolerability—BMN 390 did not meet immunogenicity benchmarks and will not move forward. Key points: ✅ BMN 390 was intended as a successor to Palynziq with better tolerability and lower viscosity. ❌ Discontinued following a strategic R&D review after failure to meet target thresholds. 🔄 BioMarin confirmed that employees were redeployed within the organization. 🧪 The company remains committed to its PKU portfolio, including the adolescent expansion of Palynziq and gene therapy efforts like BMN 307, alongside R&D in genetic diseases including achondroplasia and alpha-1 antitrypsin deficiency. This move reinforces BioMarin’s disciplined pipeline curation—prioritizing only assets with clear clinical and differentiating potential. The dependable PKU franchise, led by Palynziq, continues to grow (Q2 2025 sales up ~20% YoY at $106M), with a label expansion filing for adolescents expected by year-end. reddit.com 14biomarin.com 14fiercebiotech.com 14fiercebiotech.com 1reddit.com 1investors.biomarin.com #BioMarin #PKU #BMN390 #Palynziq #DiscontinuedProgram #RareDisease #GeneticTherapy #PipelineStrategy

💸 Imunon Shelves COVID Vaccine, Seeks Partner as Cash Dwindles 🧬 Imunon has had to deprioritize its COVID‑19 vaccine program (IMNN‑101) after its cash reserves dipped under $5 million by June 2025, prompting a refocus and urgent pursuit of strategic collaboration. The company reported that its funds now only support operations into Q4 2025, despite $3.1M added in July. 📊 While six-month Phase 1 data for IMNN‑101 showed decent immunogenicity (a 3× boost in antibody titers), market demand for COVID boosters has waned. Imunon is now prioritizing its lead immuno-oncology asset, IMNN‑001, currently entering Phase 3 OVATION‑3 for newly diagnosed advanced ovarian cancer—firmly shifting away from vaccine development amid funding constraints. This pivot underscores the realities small biotechs face when cash tightens—even when Proof-of-Concept data exists. Now, Imunon is exploring partnerships to salvage the PlaCCine® platform and finance its next steps. #Imunon #COVID19Vaccine #DNAvaccine #Immunotherapy #BiotechFunding #OvarianCancer #IMNN001 #PlaCCinePlatform

🔄 HMNC Misses Phase 2b Endpoint for BH‑200 but Eyes Precision Subgroup Path Forward HMNC Brain Health’s BH‑200 (vasopressin V1b antagonist) did not meet its primary endpoint in the Phase 2b OLIVE trial for stress‑axis-related major depressive disorder (MDD). The study included 338 participants, selected via a V1b polygenic score, and was the largest biomarker-stratified psychiatric study ever executed. 🙏 💡 What matters now: While the overall results fell short, the “V1b‑high” subgroup (~30% of patients) showed promising directional trends—suggesting that targeted response may still be achievable. HMNC plans further subgroup analysis and refinement of its companion diagnostic, using it to design a more focused relaunch in Phase 3. Parallel pipeline assets such as tildacerfont (CRF1 antagonist) with Spruce Biosciences and oral KET01 ketamine formulation for TRD remain active and on track. This recalibration underscores the challenges and potential of precision psychiatry: broad failures don’t preclude biologically informed success. The true test now lies in whether HMNC can convert subgroup efficacy into regulatory and clinical traction in the next phase. 🔬 #PrecisionPsychiatry #HMNCBrainHealth #BH200 #V1b #MDD #ClinicalTrials #BiomarkerStratification #MentalHealthInnovation